Relative Contribution of Insulin and Its Precursors to Fibrinogen and PAI-1 in a Large Population With Different States of Glucose Tolerance: The Insulin Resistance Atherosclerosis Study (IRAS)

Hyperinsulinemia is associated with the development of coronary heart disease. However, the underlying mechanisms are still poorly understood. Hypercoagulability and impaired fibrinolysis are possible candidates linking hyperinsulinism with atherosclerotic disease, and it has been suggested that pro...

Full description

Saved in:
Bibliographic Details
Published inArteriosclerosis, thrombosis, and vascular biology Vol. 19; no. 3; pp. 562 - 568
Main Authors Festa, Andreas, D'Agostino, Ralph, Mykkanen, Leena, Tracy, Russell P., Zaccaro, Daniel J., Hales, C. Nick, Haffner, Steven M.
Format Journal Article
LanguageEnglish
Published Philadelphia, PA American Heart Association, Inc 01.03.1999
Hagerstown, MD Lippincott
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Hyperinsulinemia is associated with the development of coronary heart disease. However, the underlying mechanisms are still poorly understood. Hypercoagulability and impaired fibrinolysis are possible candidates linking hyperinsulinism with atherosclerotic disease, and it has been suggested that proinsulin rather than insulin is the crucial pathophysiological agent. The aim of this study was to investigate the relationship of insulin and its precursors to markers of coagulation and fibrinolysis in a large triethnic population. A strong and independent relationship between plasminogen activator inhibitor-1 (PAI-1) antigen and insulin and its precursors (proinsulin, 32-33 split proinsulin) was found consistently across varying states of glucose tolerance (PAI-1 versus fasting insulin [proinsulin], r=0.38 [r=0.34] in normal glucose tolerance; r=0.42 [r=0.43] in impaired glucose tolerance; and r=0.38 [r=0.26] in type 2 diabetes; all P<0.001). The relationship remained highly significant even after accounting for insulin sensitivity as measured by a frequently sampled intravenous glucose tolerance test. In a stepwise multiple regression model after adjusting for age, sex, ethnicity, and clinic, both insulin and its precursors were significantly associated with PAI-1 levels. The relationship between fibrinogen and insulin and its precursors was significant in the overall population (r=0.20 for insulin and proinsulin; each P<0.001) but showed a more inconsistent pattern in subgroup analysis and after adjustments for demographic and metabolic variables. Stepwise multiple regression analysis showed that proinsulin (split products) but not fasting insulin significantly contributed to fibrinogen levels after adjustment for age, sex, clinic, and ethnicity. Decreased insulin sensitivity was independently associated with higher PAI-1 and fibrinogen levels. In summary, we were able to demonstrate an independent relationship of 2 crucial factors of hemostasis, fibrinogen and PAI-1, to insulin and its precursors. These findings may have important clinical implications in the risk assessment and prevention of macrovascular disease, not only in patients with overt diabetes but also in nondiabetic subjects who are hyperinsulinemic. (Arterioscler Thromb Vasc Biol. 1999;19:562-568.)
AbstractList Abstract —Hyperinsulinemia is associated with the development of coronary heart disease. However, the underlying mechanisms are still poorly understood. Hypercoagulability and impaired fibrinolysis are possible candidates linking hyperinsulinism with atherosclerotic disease, and it has been suggested that proinsulin rather than insulin is the crucial pathophysiological agent. The aim of this study was to investigate the relationship of insulin and its precursors to markers of coagulation and fibrinolysis in a large triethnic population. A strong and independent relationship between plasminogen activator inhibitor-1 (PAI-1) antigen and insulin and its precursors (proinsulin, 32-33 split proinsulin) was found consistently across varying states of glucose tolerance (PAI-1 versus fasting insulin [proinsulin], r =0.38 [ r =0.34] in normal glucose tolerance; r =0.42 [ r =0.43] in impaired glucose tolerance; and r =0.38 [ r =0.26] in type 2 diabetes; all P <0.001). The relationship remained highly significant even after accounting for insulin sensitivity as measured by a frequently sampled intravenous glucose tolerance test. In a stepwise multiple regression model after adjusting for age, sex, ethnicity, and clinic, both insulin and its precursors were significantly associated with PAI-1 levels. The relationship between fibrinogen and insulin and its precursors was significant in the overall population ( r =0.20 for insulin and proinsulin; each P <0.001) but showed a more inconsistent pattern in subgroup analysis and after adjustments for demographic and metabolic variables. Stepwise multiple regression analysis showed that proinsulin (split products) but not fasting insulin significantly contributed to fibrinogen levels after adjustment for age, sex, clinic, and ethnicity. Decreased insulin sensitivity was independently associated with higher PAI-1 and fibrinogen levels. In summary, we were able to demonstrate an independent relationship of 2 crucial factors of hemostasis, fibrinogen and PAI-1, to insulin and its precursors. These findings may have important clinical implications in the risk assessment and prevention of macrovascular disease, not only in patients with overt diabetes but also in nondiabetic subjects who are hyperinsulinemic.
Hyperinsulinemia is associated with the development of coronary heart disease. However, the underlying mechanisms are still poorly understood. Hypercoagulability and impaired fibrinolysis are possible candidates linking hyperinsulinism with atherosclerotic disease, and it has been suggested that proinsulin rather than insulin is the crucial pathophysiological agent. The aim of this study was to investigate the relationship of insulin and its precursors to markers of coagulation and fibrinolysis in a large triethnic population. A strong and independent relationship between plasminogen activator inhibitor-1 (PAI-1) antigen and insulin and its precursors (proinsulin, 32-33 split proinsulin) was found consistently across varying states of glucose tolerance (PAI-1 versus fasting insulin [proinsulin], r=0.38 [r=0.34] in normal glucose tolerance; r=0.42 [r=0.43] in impaired glucose tolerance; and r=0.38 [r=0.26] in type 2 diabetes; all P<0.001). The relationship remained highly significant even after accounting for insulin sensitivity as measured by a frequently sampled intravenous glucose tolerance test. In a stepwise multiple regression model after adjusting for age, sex, ethnicity, and clinic, both insulin and its precursors were significantly associated with PAI-1 levels. The relationship between fibrinogen and insulin and its precursors was significant in the overall population (r=0.20 for insulin and proinsulin; each P<0.001) but showed a more inconsistent pattern in subgroup analysis and after adjustments for demographic and metabolic variables. Stepwise multiple regression analysis showed that proinsulin (split products) but not fasting insulin significantly contributed to fibrinogen levels after adjustment for age, sex, clinic, and ethnicity. Decreased insulin sensitivity was independently associated with higher PAI-1 and fibrinogen levels. In summary, we were able to demonstrate an independent relationship of 2 crucial factors of hemostasis, fibrinogen and PAI-1, to insulin and its precursors. These findings may have important clinical implications in the risk assessment and prevention of macrovascular disease, not only in patients with overt diabetes but also in nondiabetic subjects who are hyperinsulinemic.
Hyperinsulinemia is associated with the development of coronary heart disease. However, the underlying mechanisms are still poorly understood. Hypercoagulability and impaired fibrinolysis are possible candidates linking hyperinsulinism with atherosclerotic disease, and it has been suggested that proinsulin rather than insulin is the crucial pathophysiological agent. The aim of this study was to investigate the relationship of insulin and its precursors to markers of coagulation and fibrinolysis in a large triethnic population. A strong and independent relationship between plasminogen activator inhibitor-1 (PAI-1) antigen and insulin and its precursors (proinsulin, 32-33 split proinsulin) was found consistently across varying states of glucose tolerance (PAI-1 versus fasting insulin [proinsulin], r=0.38 [r=0.34] in normal glucose tolerance; r=0.42 [r=0.43] in impaired glucose tolerance; and r=0.38 [r=0.26] in type 2 diabetes; all P<0.001). The relationship remained highly significant even after accounting for insulin sensitivity as measured by a frequently sampled intravenous glucose tolerance test. In a stepwise multiple regression model after adjusting for age, sex, ethnicity, and clinic, both insulin and its precursors were significantly associated with PAI-1 levels. The relationship between fibrinogen and insulin and its precursors was significant in the overall population (r=0.20 for insulin and proinsulin; each P<0.001) but showed a more inconsistent pattern in subgroup analysis and after adjustments for demographic and metabolic variables. Stepwise multiple regression analysis showed that proinsulin (split products) but not fasting insulin significantly contributed to fibrinogen levels after adjustment for age, sex, clinic, and ethnicity. Decreased insulin sensitivity was independently associated with higher PAI-1 and fibrinogen levels. In summary, we were able to demonstrate an independent relationship of 2 crucial factors of hemostasis, fibrinogen and PAI-1, to insulin and its precursors. These findings may have important clinical implications in the risk assessment and prevention of macrovascular disease, not only in patients with overt diabetes but also in nondiabetic subjects who are hyperinsulinemic. (Arterioscler Thromb Vasc Biol. 1999;19:562-568.)
Hyperinsulinemia is associated with the development of coronary heart disease. However, the underlying mechanisms are still poorly understood. Hypercoagulability and impaired fibrinolysis are possible candidates linking hyperinsulinism with atherosclerotic disease, and it has been suggested that proinsulin rather than insulin is the crucial pathophysiological agent. The aim of this study was to investigate the relationship of insulin and its precursors to markers of coagulation and fibrinolysis in a large triethnic population. A strong and independent relationship between plasminogen activator inhibitor-1 (PAI-1) antigen and insulin and its precursors (proinsulin, 32-33 split proinsulin) was found consistently across varying states of glucose tolerance (PAI-1 versus fasting insulin [proinsulin], r=0.38 [r=0.34] in normal glucose tolerance; r=0.42 [r=0.43] in impaired glucose tolerance; and r=0.38 [r=0.26] in type 2 diabetes; all P<0.001). The relationship remained highly significant even after accounting for insulin sensitivity as measured by a frequently sampled intravenous glucose tolerance test. In a stepwise multiple regression model after adjusting for age, sex, ethnicity, and clinic, both insulin and its precursors were significantly associated with PAI-1 levels. The relationship between fibrinogen and insulin and its precursors was significant in the overall population (r=0.20 for insulin and proinsulin; each P<0.001) but showed a more inconsistent pattern in subgroup analysis and after adjustments for demographic and metabolic variables. Stepwise multiple regression analysis showed that proinsulin (split products) but not fasting insulin significantly contributed to fibrinogen levels after adjustment for age, sex, clinic, and ethnicity. Decreased insulin sensitivity was independently associated with higher PAI-1 and fibrinogen levels. In summary, we were able to demonstrate an independent relationship of 2 crucial factors of hemostasis, fibrinogen and PAI-1, to insulin and its precursors. These findings may have important clinical implications in the risk assessment and prevention of macrovascular disease, not only in patients with overt diabetes but also in nondiabetic subjects who are hyperinsulinemic.Hyperinsulinemia is associated with the development of coronary heart disease. However, the underlying mechanisms are still poorly understood. Hypercoagulability and impaired fibrinolysis are possible candidates linking hyperinsulinism with atherosclerotic disease, and it has been suggested that proinsulin rather than insulin is the crucial pathophysiological agent. The aim of this study was to investigate the relationship of insulin and its precursors to markers of coagulation and fibrinolysis in a large triethnic population. A strong and independent relationship between plasminogen activator inhibitor-1 (PAI-1) antigen and insulin and its precursors (proinsulin, 32-33 split proinsulin) was found consistently across varying states of glucose tolerance (PAI-1 versus fasting insulin [proinsulin], r=0.38 [r=0.34] in normal glucose tolerance; r=0.42 [r=0.43] in impaired glucose tolerance; and r=0.38 [r=0.26] in type 2 diabetes; all P<0.001). The relationship remained highly significant even after accounting for insulin sensitivity as measured by a frequently sampled intravenous glucose tolerance test. In a stepwise multiple regression model after adjusting for age, sex, ethnicity, and clinic, both insulin and its precursors were significantly associated with PAI-1 levels. The relationship between fibrinogen and insulin and its precursors was significant in the overall population (r=0.20 for insulin and proinsulin; each P<0.001) but showed a more inconsistent pattern in subgroup analysis and after adjustments for demographic and metabolic variables. Stepwise multiple regression analysis showed that proinsulin (split products) but not fasting insulin significantly contributed to fibrinogen levels after adjustment for age, sex, clinic, and ethnicity. Decreased insulin sensitivity was independently associated with higher PAI-1 and fibrinogen levels. In summary, we were able to demonstrate an independent relationship of 2 crucial factors of hemostasis, fibrinogen and PAI-1, to insulin and its precursors. These findings may have important clinical implications in the risk assessment and prevention of macrovascular disease, not only in patients with overt diabetes but also in nondiabetic subjects who are hyperinsulinemic.
Author Zaccaro, Daniel J.
Haffner, Steven M.
Hales, C. Nick
Mykkanen, Leena
Festa, Andreas
Tracy, Russell P.
D'Agostino, Ralph
AuthorAffiliation Received April 21, 1998; revision accepted August 13, 1998. From the Department of Medicine, Division of Clinical Epidemiology, University of Texas Health Science Center at San Antonio (A.F., L.M., S.M.H.); the Department of Public Health Sciences, Bowman Gray School of Medicine, Winston Salem, NC (R.D., D.J.Z.); the Department of Pathology, University of Vermont School of Medicine, Burlington (R.P.T.); and the Department of Clinical Biochemistry, University of Cambridge, Cambridge, UK (C.N.H.). Correspondence to Andreas Festa, MD, Department of Medicine, Division of Clinical Epidemiology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78284-7873. E-mail festa@uthscsa.edu
AuthorAffiliation_xml – name: Received April 21, 1998; revision accepted August 13, 1998. From the Department of Medicine, Division of Clinical Epidemiology, University of Texas Health Science Center at San Antonio (A.F., L.M., S.M.H.); the Department of Public Health Sciences, Bowman Gray School of Medicine, Winston Salem, NC (R.D., D.J.Z.); the Department of Pathology, University of Vermont School of Medicine, Burlington (R.P.T.); and the Department of Clinical Biochemistry, University of Cambridge, Cambridge, UK (C.N.H.). Correspondence to Andreas Festa, MD, Department of Medicine, Division of Clinical Epidemiology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78284-7873. E-mail festa@uthscsa.edu
Author_xml – sequence: 1
  givenname: Andreas
  surname: Festa
  fullname: Festa, Andreas
  organization: Received April 21, 1998; revision accepted August 13, 1998. From the Department of Medicine, Division of Clinical Epidemiology, University of Texas Health Science Center at San Antonio (A.F., L.M., S.M.H.); the Department of Public Health Sciences, Bowman Gray School of Medicine, Winston Salem, NC (R.D., D.J.Z.); the Department of Pathology, University of Vermont School of Medicine, Burlington (R.P.T.); and the Department of Clinical Biochemistry, University of Cambridge, Cambridge, UK (C.N.H.). Correspondence to Andreas Festa, MD, Department of Medicine, Division of Clinical Epidemiology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78284-7873. E-mail festa@uthscsa.edu
– sequence: 2
  givenname: Ralph
  surname: D'Agostino
  fullname: D'Agostino, Ralph
– sequence: 3
  givenname: Leena
  surname: Mykkanen
  fullname: Mykkanen, Leena
– sequence: 4
  givenname: Russell P.
  surname: Tracy
  fullname: Tracy, Russell P.
– sequence: 5
  givenname: Daniel J.
  surname: Zaccaro
  fullname: Zaccaro, Daniel J.
– sequence: 6
  givenname: C. Nick
  surname: Hales
  fullname: Hales, C. Nick
– sequence: 7
  givenname: Steven M.
  surname: Haffner
  fullname: Haffner, Steven M.
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1714088$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/10073958$$D View this record in MEDLINE/PubMed
BookMark eNp9kkuP0zAUhSM0iHnAmh3yAiFYpGPHjpOwqwozVKpE1SmwtFznempw7WI7jObn8c9waHmIBQs_9Z1zdX18Xpw476AonhI8IYSTS0wm0_XHCekmdFLz6kFxRuqKlYxTfpL3uOnKmrPqtDiP8TPGmFUVflScEowb2tXtWfF9BVYm8w3QzLsUzGZIxjvkNZq7OFjjkHQ9mqeIlgHUEKIPESWPrswmGOdv4QAsp_OSoJFGCxluAS39fhiNs9cnk7bojdEaAriEbpJMEMcK13ZQPgJaewtBOgWv0XoLvwuvIJqYxns0TVsIPio7ziZmj6G_Ry_nq-nNq8fFQy1thCfH9aL4cPV2PXtXLt5fz2fTRalY7rvsK90SaFvG2xa6FkumJe4ZadQGOtbrtiIKq1pDQ_uWMko1h7ppZMVpz6Gq6UXx4uC7D_7rADGJnYkKrJUO_BAF7zhpGeky-OwIDpsd9GIfzE6Ge_Hr0TPw_AjIqKTVY-8m_uEawnA7YpcHTOWmYwD9l5MY0xeYiJy-IJ2gIqefFfU_CmXSzxBSkMb-R8cOujtvE4T4xQ53EMQWpE1bMX4bynFdkq7rMM3HMg_C6A8mUMQ-
CODEN ATVBFA
CitedBy_id crossref_primary_10_1016_j_medj_2020_06_005
crossref_primary_10_2337_diabetes_53_3_663
crossref_primary_10_1016_j_ecl_2006_06_001
crossref_primary_10_1016_j_ijcard_2005_04_024
crossref_primary_10_1016_j_schres_2007_03_029
crossref_primary_10_1136_bmjopen_2016_013894
crossref_primary_10_1507_endocrj_52_89
crossref_primary_10_3390_nu9040336
crossref_primary_10_2337_db15_1141
crossref_primary_10_1016_j_atherosclerosis_2006_12_018
crossref_primary_10_1016_S0149_2918_01_80140_5
crossref_primary_10_2337_diabetes_53_2_336
crossref_primary_10_2337_diacare_28_10_2472
crossref_primary_10_1016_S0300_8932_01_76390_7
crossref_primary_10_1053_meta_2003_50027
crossref_primary_10_1016_j_carpath_2007_07_007
crossref_primary_10_1016_j_thromres_2006_09_013
crossref_primary_10_1038_sj_ijo_0802192
crossref_primary_10_1210_clinem_dgz171
crossref_primary_10_1371_journal_pone_0067949
crossref_primary_10_4158_EP_13_6_679
crossref_primary_10_1155_2012_635472
crossref_primary_10_1016_j_ejvs_2009_10_014
crossref_primary_10_1016_j_rec_2010_10_011
crossref_primary_10_1016_j_metabol_2006_02_023
crossref_primary_10_1016_j_numecd_2008_07_007
crossref_primary_10_1016_S0002_9149_03_00612_X
crossref_primary_10_1007_s00296_008_0781_7
crossref_primary_10_1016_j_arteri_2018_01_002
crossref_primary_10_1177_0003319715602414
crossref_primary_10_1177_153537020122600103
crossref_primary_10_1038_sj_ijo_0801792
crossref_primary_10_18705_1607_419X_2007_13_2_113_118
crossref_primary_10_3748_wjg_v11_i32_5047
crossref_primary_10_1097_01_crd_0000182411_88146_72
crossref_primary_10_1111_j_1600_0404_2008_01080_x
crossref_primary_10_1016_S0895_7967_02_70021_5
crossref_primary_10_1517_14728222_2013_764991
crossref_primary_10_2337_diacare_28_9_2289
crossref_primary_10_3390_ijms25052661
crossref_primary_10_2337_diacare_29_03_06_dc05_2023
crossref_primary_10_1046_j_1464_5491_2002_00824_x
crossref_primary_10_1079_PHN2003586
crossref_primary_10_1016_S0149_2918_04_90017_3
crossref_primary_10_1016_j_numecd_2007_02_015
crossref_primary_10_1210_jcem_85_7_6677
crossref_primary_10_1016_S0049_3848_01_00293_6
crossref_primary_10_1186_s12902_021_00837_z
crossref_primary_10_1016_j_schres_2008_03_004
crossref_primary_10_1177_193229681200600318
crossref_primary_10_1097_SMJ_0b013e3181cf373f
crossref_primary_10_1097_00041433_200010000_00010
crossref_primary_10_1177_039463200702000312
crossref_primary_10_2337_diabetes_53_7_1773
crossref_primary_10_1016_S0755_4982_05_84243_5
crossref_primary_10_1016_j_jdiacomp_2006_02_001
crossref_primary_10_1016_j_surg_2010_05_014
crossref_primary_10_1016_j_jacc_2004_11_075
crossref_primary_10_1073_pnas_2121133119
crossref_primary_10_1097_TEN_0b013e3181dfe618
crossref_primary_10_1152_ajpendo_00064_2015
crossref_primary_10_1111_j_1749_6632_2001_tb03936_x
crossref_primary_10_1016_j_jacc_2008_10_038
crossref_primary_10_1172_JCI13143
crossref_primary_10_2337_db06_0116
crossref_primary_10_1002_pro_3770
crossref_primary_10_1152_ajpheart_00620_2011
crossref_primary_10_1016_j_schres_2014_08_011
crossref_primary_10_1038_jcbfm_2010_102
crossref_primary_10_1007_s00125_005_1711_9
crossref_primary_10_1590_S1807_59322006000500010
crossref_primary_10_1111_j_1464_5491_2006_01923_x
crossref_primary_10_1111_j_1440_1797_2010_01329_x
crossref_primary_10_1093_jbcr_irz083
crossref_primary_10_1177_1010539513480233
crossref_primary_10_1055_s_0041_1726613
crossref_primary_10_2337_diacare_24_8_1476
crossref_primary_10_2337_dc07_0637
crossref_primary_10_2337_diacare_25_10_1737
crossref_primary_10_3389_fcvm_2021_769343
crossref_primary_10_1016_j_jdiacomp_2016_06_030
crossref_primary_10_2174_1389201021666201126143217
crossref_primary_10_1134_S2079057015040128
crossref_primary_10_1177_0300060515627561
crossref_primary_10_3132_dvdr_2004_011
crossref_primary_10_1002_dmrr_254
crossref_primary_10_1016_j_eclinm_2020_100548
crossref_primary_10_1016_j_thromres_2010_12_005
crossref_primary_10_1089_154041903321648243
crossref_primary_10_1590_S0004_27302008000300015
crossref_primary_10_1002_ddr_20233
crossref_primary_10_1016_j_jvs_2012_05_078
crossref_primary_10_14341_2072_0351_5995
crossref_primary_10_1016_S0889_8588_02_00086_2
crossref_primary_10_1111_j_1538_7836_2008_03176_x
crossref_primary_10_2337_diabetes_51_4_1131
crossref_primary_10_2337_dc07_1540
crossref_primary_10_1016_S0021_9150_01_00574_3
crossref_primary_10_1007_s00125_007_0715_z
crossref_primary_10_1053_j_semvascsurg_2016_06_003
crossref_primary_10_1016_S0005_2736_02_00686_7
crossref_primary_10_2337_dc08_1795
crossref_primary_10_1152_ajpregu_00093_2009
crossref_primary_10_1111_j_1365_2796_2004_01371_x
crossref_primary_10_2337_diacare_25_3_524
crossref_primary_10_1016_j_annepidem_2017_12_003
crossref_primary_10_1038_nrneurol_2009_231
crossref_primary_10_1016_j_thromres_2009_11_034
crossref_primary_10_1210_jc_2003_030508
crossref_primary_10_18705_1607_419X_2006_12_2_99_116
crossref_primary_10_1016_j_jvs_2010_05_086
crossref_primary_10_1111_j_1365_2265_2007_03113_x
crossref_primary_10_1016_j_amjcard_2006_02_022
crossref_primary_10_1111_j_1538_7836_2006_02132_x
crossref_primary_10_2337_diabetes_53_6_1549
crossref_primary_10_1080_03008200701331524
crossref_primary_10_1016_S1062_0303_03_00083_9
crossref_primary_10_1046_j_1467_789X_2002_00056_x
crossref_primary_10_1080_07853890500401234
crossref_primary_10_1186_1475_2840_13_76
crossref_primary_10_1007_s10900_013_9726_5
crossref_primary_10_1097_YIC_0b013e32801182e6
crossref_primary_10_2337_diabetes_54_5_1566
crossref_primary_10_3389_fcvm_2021_653655
crossref_primary_10_1093_aje_153_3_242
crossref_primary_10_1016_j_amjmed_2003_08_009
crossref_primary_10_1016_j_recesp_2010_10_010
crossref_primary_10_2188_jea_16_64
crossref_primary_10_1038_oby_2002_98
crossref_primary_10_1016_j_numecd_2009_08_006
crossref_primary_10_1016_S0021_9150_01_00575_5
crossref_primary_10_1046_j_1538_7836_2003_00276_x
crossref_primary_10_1016_S1134_3230_10_61006_X
crossref_primary_10_1007_s10557_008_6101_3
crossref_primary_10_1016_j_ecl_2004_03_008
crossref_primary_10_1016_j_thromres_2014_02_028
crossref_primary_10_1097_MAJ_0b013e3182449ff9
crossref_primary_10_1007_s11892_003_0056_3
crossref_primary_10_1038_srep17714
crossref_primary_10_1046_j_1523_1755_2000_00331_x
crossref_primary_10_1016_j_diabres_2005_10_015
crossref_primary_10_1111_j_1365_2796_2007_01824_x
crossref_primary_10_2165_00003495_200565010_00003
crossref_primary_10_1016_j_jdiacomp_2006_10_009
crossref_primary_10_1038_s41380_021_01264_1
crossref_primary_10_1079_PNS2005482
crossref_primary_10_1016_j_amjmed_2003_08_014
crossref_primary_10_19163_1994_9480_2017_3_63__16_22
crossref_primary_10_1007_s00125_012_2741_8
crossref_primary_10_1016_j_artere_2018_01_001
crossref_primary_10_1016_j_jstrokecerebrovasdis_2012_12_014
crossref_primary_10_14341_2072_0351_6114
crossref_primary_10_1007_s12975_014_0365_7
crossref_primary_10_1016_j_jacc_2015_06_1328
crossref_primary_10_1016_j_vph_2005_11_009
crossref_primary_10_1186_1476_9255_8_34
crossref_primary_10_1046_j_1365_2265_2003_01714_x
crossref_primary_10_1097_00005082_200607000_00012
crossref_primary_10_1089_met_2005_3_147
crossref_primary_10_1586_eem_09_44
crossref_primary_10_1038_s41598_018_30028_1
crossref_primary_10_2165_00129784_200606040_00003
crossref_primary_10_1007_s00125_005_1876_2
Cites_doi 10.1056/NEJM198708063170605
10.1016/1047-2797(95)00062-3
10.2337/diab.44.1.37
10.1093/oxfordjournals.aje.a115134
10.1172/JCI111776
10.1007/BF00404140
10.1016/1047-2797(92)90095-8
10.1161/circ.89.1.8281664
10.2337/diab.41.6.715
10.2337/diab.42.9.1297
10.1016/0049-3848(90)90373-K
10.1016/0026-0495(88)90157-6
10.1055/s-0038-1650395
10.1161/atv91.13.12.8241109
10.1016/0002-8703(90)90026-T
10.1055/s-0038-1653822
10.1016/0895-4356(94)90298-4
10.2337/diab.43.1.104
10.2337/diab.36.8.897
10.2337/diab.42.2.250
10.2337/diab.43.9.1114
10.1161/circ.93.10.1809
10.1016/S0021-9150(96)06070-4
10.1093/oxfordjournals.aje.a113956
10.1007/BF02374497
10.2337/diacare.13.6.631
10.2337/diab.44.4.437
10.1055/s-0038-1646997
10.2337/diacare.19.2.157
10.1093/oxfordjournals.aje.a116768
10.1016/0026-0495(90)90164-8
10.1042/bj2600535
10.1210/edrv-6-1-45
10.3109/07853899608999095
10.1007/BF00402183
10.1055/s-0038-1653762
10.7326/0003-4819-118-12-199306150-00008
10.2337/diacare.15.10.1245
10.1016/S0140-6736(89)91306-8
10.1111/j.0954-6820.1985.tb08888.x
10.1007/BF00403280
10.1056/NEJM198408233110804
10.1161/circ.91.3.764
10.1210/jcem-71-6-1508
10.1093/oxfordjournals.aje.a113639
10.2337/diab.37.12.1595
10.1007/BF00400356
10.1056/NEJM198903163201105
10.1016/0026-0495(93)90005-9
10.1016/0026-0495(86)90209-X
10.1159/000205234
10.2337/diab.41.7.890
10.1016/0169-2607(86)90106-9
10.1161/atvb.18.1.84
10.2337/diacare.14.3.173
10.1210/jcem-25-10-1375
10.1016/0026-0495(88)90133-3
ContentType Journal Article
Copyright 1999 American Heart Association, Inc.
1999 INIST-CNRS
Copyright_xml – notice: 1999 American Heart Association, Inc.
– notice: 1999 INIST-CNRS
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1161/01.ATV.19.3.562
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1524-4636
EndPage 568
ExternalDocumentID 10073958
1714088
10_1161_01_ATV_19_3_562
00043605-199903000-00014
Genre Research Support, U.S. Gov't, P.H.S
Journal Article
GrantInformation_xml – fundername: NHLBI NIH HHS
  grantid: HL47889
– fundername: NHLBI NIH HHS
  grantid: HL47890
– fundername: NHLBI NIH HHS
  grantid: HL47887
GroupedDBID ---
.3C
.55
.GJ
.Z2
01R
0R~
1J1
23N
2WC
3O-
40H
4Q1
4Q2
4Q3
53G
5GY
5RE
5VS
71W
77Y
7O~
AAAAV
AAAXR
AAGIX
AAHPQ
AAIQE
AAMOA
AAMTA
AAQKA
AARTV
AASCR
AASOK
AAXQO
ABASU
ABBUW
ABDIG
ABJNI
ABPXF
ABQRW
ABVCZ
ABXVJ
ABZAD
ABZZY
ACCJW
ACDDN
ACEWG
ACGFS
ACGOD
ACILI
ACLDA
ACPRK
ACWDW
ACWRI
ACXJB
ACXNZ
ACZKN
ADBBV
ADFPA
ADGGA
ADHPY
ADNKB
AE3
AE6
AEETU
AENEX
AFBFQ
AFDTB
AFFNX
AFUWQ
AGINI
AHJKT
AHMBA
AHOMT
AHQNM
AHRYX
AHVBC
AIJEX
AINUH
AJCLO
AJIOK
AJNWD
AJNYG
AJZMW
AKCTQ
AKULP
ALKUP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AOQMC
AYCSE
BAWUL
BOYCO
BQLVK
BS7
C1A
C45
CS3
DIK
DIWNM
DUNZO
E.X
E3Z
EBS
EEVPB
EJD
ERAAH
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
FL-
FRP
FW0
GNXGY
GQDEL
GX1
H0~
H13
HLJTE
HZ~
IKREB
IKYAY
IN~
IPNFZ
J5H
JF9
JG8
JK3
JK8
K8S
KD2
KMI
KQ8
L-C
L7B
N9A
N~7
N~B
N~M
O9-
OAG
OAH
OB2
OCUKA
ODA
OL1
OLG
OLH
OLU
OLV
OLY
OLZ
OPUJH
ORVUJ
OUVQU
OVD
OVDNE
OVIDH
OVLEI
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P-K
P2P
PQQKQ
PZZ
RAH
RIG
RLZ
S4R
S4S
T8P
TEORI
TR2
TSPGW
V2I
VVN
W3M
W8F
WOQ
WOW
X3V
X3W
X7M
XXN
XYM
YFH
ZGI
ZZMQN
AAYXX
ADGHP
CITATION
IQODW
ACIJW
AWKKM
CGR
CUY
CVF
ECM
EIF
NPM
OK1
OLW
RHF
7X8
ID FETCH-LOGICAL-c4004-d2f81e884688e980a4fa0d417cbe94df821c0c5fe73d83433f6e577a263d6e253
ISSN 1079-5642
IngestDate Fri Jul 11 12:42:06 EDT 2025
Wed Feb 19 02:34:28 EST 2025
Mon Jul 21 09:12:40 EDT 2025
Tue Jul 01 02:21:41 EDT 2025
Thu Apr 24 23:05:09 EDT 2025
Fri May 16 03:46:45 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Endocrinopathy
Vascular disease
Human
Plasminogen activator inhibitor 1
Target tissue resistance
Atherosclerosis
Risk factor
Fibrinogen
Cardiovascular disease
Non insulin dependent diabetes
Insulin
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c4004-d2f81e884688e980a4fa0d417cbe94df821c0c5fe73d83433f6e577a263d6e253
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 10073958
PQID 69618419
PQPubID 23479
PageCount 7
ParticipantIDs proquest_miscellaneous_69618419
pubmed_primary_10073958
pascalfrancis_primary_1714088
crossref_primary_10_1161_01_ATV_19_3_562
crossref_citationtrail_10_1161_01_ATV_19_3_562
wolterskluwer_health_00043605-199903000-00014
ProviderPackageCode CITATION
AAYXX
PublicationCentury 1900
PublicationDate 1999-March
PublicationDateYYYYMMDD 1999-03-01
PublicationDate_xml – month: 03
  year: 1999
  text: 1999-March
PublicationDecade 1990
PublicationPlace Philadelphia, PA
Hagerstown, MD
PublicationPlace_xml – name: Philadelphia, PA
– name: Hagerstown, MD
– name: United States
PublicationTitle Arteriosclerosis, thrombosis, and vascular biology
PublicationTitleAlternate Arterioscler Thromb Vasc Biol
PublicationYear 1999
Publisher American Heart Association, Inc
Lippincott
Publisher_xml – name: American Heart Association, Inc
– name: Lippincott
References e_1_3_2_26_2
e_1_3_2_49_2
e_1_3_2_28_2
(e_1_3_2_53_2) 1995; 73
e_1_3_2_41_2
e_1_3_2_20_2
e_1_3_2_43_2
e_1_3_2_62_2
e_1_3_2_22_2
e_1_3_2_45_2
(e_1_3_2_48_2) 1993; 117
e_1_3_2_24_2
e_1_3_2_47_2
e_1_3_2_60_2
e_1_3_2_9_2
e_1_3_2_16_2
e_1_3_2_37_2
e_1_3_2_7_2
e_1_3_2_18_2
e_1_3_2_39_2
e_1_3_2_1_2
e_1_3_2_54_2
e_1_3_2_10_2
e_1_3_2_31_2
e_1_3_2_52_2
e_1_3_2_5_2
e_1_3_2_12_2
e_1_3_2_33_2
e_1_3_2_58_2
e_1_3_2_14_2
e_1_3_2_35_2
(e_1_3_2_56_2) 1996; 75
e_1_3_2_50_2
(e_1_3_2_3_2) 1996; 334
(e_1_3_2_46_2) 1994; 118
e_1_3_2_27_2
e_1_3_2_29_2
(e_1_3_2_55_2) 1997; 8
e_1_3_2_40_2
e_1_3_2_21_2
e_1_3_2_42_2
e_1_3_2_63_2
e_1_3_2_23_2
e_1_3_2_44_2
e_1_3_2_25_2
e_1_3_2_61_2
e_1_3_2_15_2
e_1_3_2_38_2
e_1_3_2_8_2
e_1_3_2_17_2
e_1_3_2_59_2
e_1_3_2_6_2
e_1_3_2_19_2
e_1_3_2_30_2
e_1_3_2_32_2
e_1_3_2_51_2
e_1_3_2_11_2
e_1_3_2_34_2
e_1_3_2_57_2
e_1_3_2_4_2
e_1_3_2_13_2
e_1_3_2_36_2
e_1_3_2_2_2
References_xml – ident: e_1_3_2_12_2
  doi: 10.1056/NEJM198708063170605
– ident: e_1_3_2_34_2
  doi: 10.1016/1047-2797(95)00062-3
– ident: e_1_3_2_57_2
  doi: 10.2337/diab.44.1.37
– ident: e_1_3_2_36_2
  doi: 10.1093/oxfordjournals.aje.a115134
– ident: e_1_3_2_7_2
  doi: 10.1172/JCI111776
– ident: e_1_3_2_32_2
  doi: 10.1007/BF00404140
– volume: 8
  start-page: 1252
  year: 1997
  ident: e_1_3_2_55_2
  publication-title: Diabetes Care
– ident: e_1_3_2_62_2
  doi: 10.1016/1047-2797(92)90095-8
– ident: e_1_3_2_30_2
  doi: 10.1161/circ.89.1.8281664
– ident: e_1_3_2_16_2
  doi: 10.2337/diab.41.6.715
– ident: e_1_3_2_33_2
  doi: 10.2337/diab.42.9.1297
– ident: e_1_3_2_49_2
  doi: 10.1016/0049-3848(90)90373-K
– ident: e_1_3_2_13_2
  doi: 10.1016/0026-0495(88)90157-6
– volume: 75
  start-page: 921
  year: 1996
  ident: e_1_3_2_56_2
  publication-title: Thromb Haemost
  doi: 10.1055/s-0038-1650395
– ident: e_1_3_2_21_2
  doi: 10.1161/atv91.13.12.8241109
– ident: e_1_3_2_19_2
  doi: 10.1016/0002-8703(90)90026-T
– volume: 73
  start-page: 568
  year: 1995
  ident: e_1_3_2_53_2
  publication-title: Thromb Haemost
  doi: 10.1055/s-0038-1653822
– ident: e_1_3_2_50_2
  doi: 10.1016/0895-4356(94)90298-4
– ident: e_1_3_2_51_2
  doi: 10.2337/diab.43.1.104
– ident: e_1_3_2_14_2
  doi: 10.2337/diab.36.8.897
– ident: e_1_3_2_44_2
  doi: 10.2337/diab.42.2.250
– ident: e_1_3_2_45_2
  doi: 10.2337/diab.43.9.1114
– ident: e_1_3_2_5_2
  doi: 10.1161/circ.93.10.1809
– ident: e_1_3_2_29_2
  doi: 10.1016/S0021-9150(96)06070-4
– volume: 334
  start-page: 952
  year: 1996
  ident: e_1_3_2_3_2
  publication-title: Med
– ident: e_1_3_2_2_2
– ident: e_1_3_2_35_2
  doi: 10.1093/oxfordjournals.aje.a113956
– volume: 117
  start-page: 67
  year: 1993
  ident: e_1_3_2_48_2
  publication-title: Arch Pathol Lab Med
– ident: e_1_3_2_60_2
  doi: 10.1007/BF02374497
– ident: e_1_3_2_6_2
  doi: 10.2337/diacare.13.6.631
– ident: e_1_3_2_40_2
  doi: 10.2337/diab.44.4.437
– ident: e_1_3_2_54_2
  doi: 10.1055/s-0038-1646997
– ident: e_1_3_2_59_2
  doi: 10.2337/diacare.19.2.157
– ident: e_1_3_2_4_2
  doi: 10.1093/oxfordjournals.aje.a116768
– ident: e_1_3_2_22_2
  doi: 10.1016/0026-0495(90)90164-8
– ident: e_1_3_2_39_2
  doi: 10.1042/bj2600535
– ident: e_1_3_2_41_2
  doi: 10.1210/edrv-6-1-45
– ident: e_1_3_2_17_2
  doi: 10.3109/07853899608999095
– ident: e_1_3_2_23_2
  doi: 10.1007/BF00402183
– ident: e_1_3_2_52_2
  doi: 10.1055/s-0038-1653762
– ident: e_1_3_2_18_2
  doi: 10.7326/0003-4819-118-12-199306150-00008
– ident: e_1_3_2_20_2
  doi: 10.2337/diacare.15.10.1245
– ident: e_1_3_2_28_2
  doi: 10.1016/S0140-6736(89)91306-8
– ident: e_1_3_2_1_2
  doi: 10.1111/j.0954-6820.1985.tb08888.x
– ident: e_1_3_2_27_2
  doi: 10.1007/BF00403280
– ident: e_1_3_2_61_2
  doi: 10.1056/NEJM198408233110804
– ident: e_1_3_2_31_2
  doi: 10.1161/circ.91.3.764
– ident: e_1_3_2_43_2
  doi: 10.1210/jcem-71-6-1508
– ident: e_1_3_2_9_2
  doi: 10.1093/oxfordjournals.aje.a113639
– ident: e_1_3_2_15_2
  doi: 10.2337/diab.37.12.1595
– ident: e_1_3_2_26_2
  doi: 10.1007/BF00400356
– ident: e_1_3_2_37_2
– ident: e_1_3_2_8_2
  doi: 10.1056/NEJM198903163201105
– ident: e_1_3_2_25_2
  doi: 10.1016/0026-0495(93)90005-9
– ident: e_1_3_2_24_2
  doi: 10.1016/0026-0495(86)90209-X
– ident: e_1_3_2_47_2
  doi: 10.1159/000205234
– ident: e_1_3_2_58_2
  doi: 10.2337/diab.41.7.890
– ident: e_1_3_2_42_2
  doi: 10.1016/0169-2607(86)90106-9
– ident: e_1_3_2_63_2
  doi: 10.1161/atvb.18.1.84
– ident: e_1_3_2_11_2
  doi: 10.2337/diacare.14.3.173
– ident: e_1_3_2_38_2
  doi: 10.1210/jcem-25-10-1375
– ident: e_1_3_2_10_2
  doi: 10.1016/0026-0495(88)90133-3
– volume: 118
  start-page: 1106
  year: 1994
  ident: e_1_3_2_46_2
  publication-title: Arch Pathol Lab Med
SSID ssj0004220
Score 2.1065567
Snippet Hyperinsulinemia is associated with the development of coronary heart disease. However, the underlying mechanisms are still poorly understood....
Abstract —Hyperinsulinemia is associated with the development of coronary heart disease. However, the underlying mechanisms are still poorly understood....
SourceID proquest
pubmed
pascalfrancis
crossref
wolterskluwer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 562
SubjectTerms African Continental Ancestry Group
Arteriosclerosis - ethnology
Arteriosclerosis - metabolism
Asian Continental Ancestry Group
Atherosclerosis (general aspects, experimental research)
Biological and medical sciences
Blood and lymphatic vessels
Cardiology. Vascular system
Diabetes Mellitus, Type 2 - metabolism
European Continental Ancestry Group
Female
Fibrinogen - metabolism
Fibrinolysis - physiology
Glucose Tolerance Test
Humans
Hyperinsulinism - ethnology
Hyperinsulinism - metabolism
Hypoglycemic Agents - blood
Insulin - blood
Insulin Resistance - physiology
Male
Medical sciences
Middle Aged
Plasminogen Activator Inhibitor 1 - blood
Proinsulin - blood
Regression Analysis
Risk Factors
Title Relative Contribution of Insulin and Its Precursors to Fibrinogen and PAI-1 in a Large Population With Different States of Glucose Tolerance: The Insulin Resistance Atherosclerosis Study (IRAS)
URI https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00043605-199903000-00014
https://www.ncbi.nlm.nih.gov/pubmed/10073958
https://www.proquest.com/docview/69618419
Volume 19
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLaqISEkhLhTYOAHJiFNCXGcOPZjVRgDNgSoQ3uLcnFAakmmJgXBb-C38hs4vtRJp04avERJ5Nhpzxef4-Q730HoGSWEVVRkXikz5kWyIB4XpfRKQUXFk6qgujbg8Xt2eBK9PY1PR6M_A9bSqsv94tfWvJL_sSqcA7uqLNl_sKzrFE7APtgXtmBh2F7KxobJ9l1Vnqtd5SqTHGIY5prs27WKaFGsILReaj2HA0Xzrxvo1uQKTN54RL33yPaPFC98_4Mr6gWTRvcVpkVTRKWzoaka4bWlus-ahVw65Dg5W6UA3bRwu-CEjYqBqsfwLV8fqXEdCdYKQfVRqQ1pNdkyc0H_yzUxQ0y-NDAz6aLh-59UtrCDzc_5PNubTvc4r818egTrdOd5wDEXBlSrttUvLf3-rYdRSljTvuxEHSTCi5lR5vKlnbzDyFMCaBuzuxigmA6m6th6AWmP-HaHwohOkvAns88-ET713XVD6e5zLtURHfUSi5E0ICl0kBKR0jRWIcOVEJY1quLGu48DdfswNOoZ9rdZKSro4MW5O9iIoq6fgb2yRWUqsWxbKkGbH41iX7RznXwxCKFmN9ENu_bBEwPkW2gk69vo6rFld9xBv9d4xkM846bCFs8YYIMBz7jHM-4a3ONZN9B4xqo11njGPZ6xwjN2eMYGz2oEi2fs8HwXnRy8mk0PPVstxCuUH_LKsOJEcoinOZeCB1lUZUEZkaTIpYjKioekCBS3MqElpxGlFZNxkmQhoyWTYUzvoZ26qeUDhCuIckORM8nKOIL1eU6TXGQyhr0wDygdI3_976eFldJXFV0W6QX2HqPn7oIzoyJzcdPdDXP27ZW0Judj9HRt3hQ8gfq8l9WyWbUp08WbiBij-8bqg6H093i41tuAQWpyrVPNB2BKkhieNPD6RmyCRA8vf9uP0LX-MX2MdrrlSu5CuN7lTzTG_wIWmufa
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Relative+Contribution+of+Insulin+and+Its+Precursors+to+Fibrinogen+and+PAI-1+in+a+Large+Population+With+Different+States+of+Glucose+Tolerance&rft.jtitle=Arteriosclerosis%2C+thrombosis%2C+and+vascular+biology&rft.au=Festa%2C+Andreas&rft.au=D%E2%80%99Agostino%2C+Ralph&rft.au=Mykka%CC%88nen%2C+Leena&rft.au=Tracy%2C+Russell+P.&rft.date=1999-03-01&rft.issn=1079-5642&rft.eissn=1524-4636&rft.volume=19&rft.issue=3&rft.spage=562&rft.epage=568&rft_id=info:doi/10.1161%2F01.ATV.19.3.562&rft.externalDBID=n%2Fa&rft.externalDocID=10_1161_01_ATV_19_3_562
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1079-5642&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1079-5642&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1079-5642&client=summon